Evidence map›Paper›PMID 19585090›Full record

ArticleHNO2009

[Cluster immunotherapy of persistent allergic rhinoconjunctivitis. Safety aspects of induction therapy with mite depot allergen preparations].

O Pfaar, R Mösges, K Hörmann, L Klimek

Abstract readEnglish Abstract
PubMed Publisher
In one paragraph

Article in HNO, 2009. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed, 1 pooled it
0.4field-weighted citation impact, top 41% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 1 synthesis or guideline pooled it, 7 citations in OpenAlex.

  1. Pooled it
  2. Review
  3. Article
  4. Safety aspects of subcutaneous immunotherapy with multiple allergens--a retrospective analysis on polysensitized patients.European archives of oto-rhino-laryngology : official journal of the European Federation of Oto-Rhino-Laryngological Societies (EUFOS) : affiliated with the German Society for Oto-Rhino-Laryngology - Head and Neck Surgery · 2010
    Article
  5. Safety aspects of Cluster immunotherapy with semi-depot allergen extracts in seasonal allergic rhinoconjunctivitis.European archives of oto-rhino-laryngology : official journal of the European Federation of Oto-Rhino-Laryngological Societies (EUFOS) : affiliated with the German Society for Oto-Rhino-Laryngology - Head and Neck Surgery · 2010
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 2 institutions in 1 country.

O PfaarHNO-Universitätsklinik, Mannheim. oliver.pfaar@hno-wiesbaden.de
R Mösges
K Hörmann
L Klimek
Heidelberg University · DEInstitute of Energy Economics at the University of Cologne · DE

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundApart from allergen avoidance and pharmacotreatment, specific immunotherapy (SIT) is the most important therapeutic option offered to allergic patients. Clinical efficacy of SIT depends on the specific allergen extract used, the quality and total cumulative amount of allergen applied and the treatment schedule of the therapy. In cluster SIT, 2-3 injections per treatment day are applied resulting in an accelerated achievement of the maintenance dose. PATIENTS AND

methodsIn this study 79 mite-sensitized adult allergic patients aged 18 to 59 years (mean 27.4+/-7.2 years) were investigated in terms of side-effects of cluster SIT during induction treatment.

resultsA total of 129 local hypersensitivity reactions (>grade 1) occurred or 10.2% of all injections (69% grade 1, 20% grade 2, 11% grade 3 and no grade 4 reactions). The total number of systemic reactions was 40 or 3.2% of all injections with 92% grade 1 and 8% grade 2 reactions. Grade 3 or 4 reactions did not occur.

conclusionCluster SIT with depot allergens represents an interesting alternative option to conventional dosage schedules of SIT.

Indexed as

AdolescentAdultAnimalsAntigens, DermatophagoidesCluster AnalysisDelayed-Action PreparationsDermatophagoides farinaeDermatophagoides pteronyssinusDesensitization, ImmunologicDose-Response Relationship, DrugDrug Administration ScheduleDrug EruptionsDrug HypersensitivityFemaleHumansIntradermal TestsAntigens, DermatophagoidesDelayed-Action Preparations

Identifiers

PMID19585090
OpenAlexW1579158476

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.